Search

Displaying results 2191 - 2200 of 7706 in total
  1. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. … Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the

    Products: APIDRA 100 U/ML- SOLUTION FOR INJECTION IN VIAL, APIDRA OPTIPEN 100 IU/ML SC KULLANIMI İÇİN ENJEKSİYONLUK ÇÖZELTİ, 5 ADET
  2. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor. … another ROS1 inhibitor has failed rather than as an alternative first choice.

  3. Drug

    Calcium glubionate anhydrous

    go.drugbank.com/drugs/DB13142
    Approved

    Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.

    Synonyms: (D-gluconato)(lactobionato)calcium, Calcium D-gluconate lactobionate
  4. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    Agmatine is both an experimental and investigational drug. … As an investigational drug, it is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy between the

  5. Drug

    Docetaxel

    go.drugbank.com/drugs/DB01248
    ApprovedInvestigational

    [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676] … [A259676] Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.

    Products: DOCETAXEL PHARMAKI GENERICS
  6. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). … [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults.

  7. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed to provide passive immunization against RSV infection as an

  8. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. … When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture" or "organotypical culture" [L2453].

  9. Drug

    Sulfadoxine

    go.drugbank.com/drugs/DB01299
    ApprovedInvestigationalWithdrawn

    A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.

  10. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).